Saturday 17 October 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million. In the quarter to June 2026, EPS grew 1.30% and free cash flow grew 50.2%, each against the same quarter a year earlier.
27.53
0.05
+0.18%
Follow MAZE
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
— | — | 1.01 | — |
P/S ratio |
— | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | 1.10 | — |
P/FCF ratio |
— | — | 0.52 | — |
P/Operating CF |
— | — | (1.73) | — |
P/B ratio |
— | — | 0.00 | — |
Price to Tangible BV |
— | — | 0.00 | — |
EV/Sales |
— | — | 0.00 | — |
EV/EBITDA |
— | — | 0.00 | — |
EV/Operating CF |
— | — | (1.82) | — |
EV/FCF |
— | — | (1.84) | — |
Quick Ratio |
4.81 | 1.79 | 9.52 | 15.16 |
Current Ratio |
5.11 | 2.09 | 9.76 | 15.50 |
Net Debt/EBITDA |
0.93 | 0.10 | (3.23) | 2.43 |
Debt/Assets |
0.00% | 28.08% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.05) | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 1.07 | 0.00 |
Operating CF/Net income |
0.86 | 0.86 | 22.31 | 0.85 |
Capex/Depreciation |
(0.51) | (0.11) | (0.35) | (0.33) |
| 0.00% | 30.60% | (0.99%) | (598.95%) | |
| 0.00% | (90.68%) | 2.18% | (41.12%) | |
ROIC |
0.00% | 0.00% | 0.00% | (684.43%) |
Return on Tangible Assets |
(117.56%) | (376.95%) | 1.81% | (39.47%) |
Average Days of Receivables |
— | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 49.85% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 15.77% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 5.76% | 0.00% |
Graham Net Nets |
— | — | (9.02) | — |
Graham Number |
— | — | 0.00 | — |
Earnings Yield |
— | — | 98.67% | — |
Free Cash Flow Yield |
— | — | 192.85% | — |
Revenue per Share |
0.00 | 0.00 | 69.91 | 0.00 |
Operating CF per Share |
(49.38) | (37.95) | 31.70 | (2.60) |
Capex per Share |
(0.98) | (0.19) | (0.48) | (0.02) |
Free Cash Flow per Share |
(50.36) | (38.14) | 31.22 | (2.62) |
Cash per Share |
49.74 | 12.74 | 82.14 | 7.96 |
Shareholders Equity per Share |
(140.60) | (163.40) | (129.88) | 8.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(140.60) | (163.40) | (129.88) | 8.26 |
Free Cash Flow |
(101.17) | (87.27) | 74.81 | (112.73) |
Working Capital |
85.37 | 17.79 | 181.00 | 327.16 |
Capital Expenditures |
(1.97) | (0.44) | (1.15) | (0.79) |
Net Current Asset Value |
(326.27) | (411.24) | (350.05) | 307.56 |
EV/EBIT |
— | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
— | — | 0.67 | — |
| Other line items | ||||
Depreciation/Fixed assets |
0.31 | 0.46 | 0.49 | 0.48 |
Cash ROIC |
55.42% | 26.88% | (65.41%) | (16.18%) |
Accounts Receivable Turnover |
— | — | 0.00 | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.80 | 1.98 | 1.87 |
Average Assets |
— | 110.73 | 156.02 | 318.83 |
Average Common Equity |
— | (328.15) | (342.52) | 21.89 |
Columns are period end dates